|Bid||45.50 x 800|
|Ask||46.09 x 800|
|Day's Range||44.72 - 46.10|
|52 Week Range||24.87 - 129.71|
|Beta (5Y Monthly)||2.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||78.46|
Subscribe to Yahoo Finance Plus to view Fair Value for ARCTLearn more
The annual LD Micro Conference was held recently and Real Money's Jim Collins was on hand to evaluate potential micro-cap stock winners. "It's the Woodstock of micro-capitalism," Collins wrote in Real Money.
LD Micro's fearless leader, Chris Lahiji, had to shut things down last year, owing to the pandemic, but, unlike other conferences scheduled for the fourth quarter, decided to go to hybrid mode this year instead of fully remote. CEOs, CFOs, buy-siders, individual investors ... everyone shows up to LD Micro.
SAN DIEGO, October 12, 2021--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vacc